Strand Therapeutics, a leader in next-generation mRNA-based therapeutics, today announced exciting preliminary Phase 1 clinical data for its lead investigational candidate, STX-001, in patients ...

A phase 1 trial of APX-343A, NOX inhibitor targeting CAF-mediated immunosuppression, as monotherapy or in combination with pembrolizumab in patients with advanced solid tumors. A phase I study of a ...

Methods: First-in-human, multicenter, phase 1 study ARC101-P1-101 (NCT06672185) aims to determine the optimal dosing, safety, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antitumor ...

Enliven won’t take its phase 1 solid tumor drug into further development next year in order to keep resources running to its leukemia candidate.

Asahi Kasei Bioprocess America and PeptiSystems have announced a strategic, exclusive partnership for the peptide manufacturing industry.

Solid Biosciences to present data on SGT-003 for Duchenne muscular dystrophy at ASGCT meeting, focusing on safety and efficacy.

While the allyloxycarbonyl (Alloc) protecting group has played a key role in solid-phase peptide synthesis (SPPS), providing access to a wide range of peptides, its removal has suffered from relying ...

This film creatively illustrates the process of protein synthesis through dance, symbolizing the assembly of amino acids into proteins. It explains how genes encode instructions for amino acid ...

The new facility in Switzerland will also dovetail with the company’s expansion of its Boulder site in Colorado, doubling CordenPharma's annual solid phase peptide synthesis (SPPS) reactor ...